Literature DB >> 19000670

Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells.

Liang Wu1, Lei Zhu, Wei-Hao Shi, Jin Zhang, Duan Ma, Bo Yu.   

Abstract

Bisphosphonates, which are extensively used in bone-related disorders, have been reported to inhibit atherosclerosis and neointimal hyperplasia. In the present study, we investigated the effects of a bisphosphonate, zoledronate, on the proliferation, adhesion, migration and microstructure of vascular smooth muscle cells (VSMCs) from Sprague-Dawley rats. It was shown that zoledronate suppressed VSMCs proliferation after 48 h cultivation in a dose depend manner, most obviously at concentrations above 10 microM. Cell cycle analysis indicated that zoledronate inhibited the proliferation of VSMCs via cell cycle arrest at S/G2/M phase. This inhibition was not associated with cell death. In a modified Boyden chamber model, it was shown that zoledronate dose-dependently inhibited VSMCs adhesion to collagen and migration stimulated by platelet-derived growth factor-BB. Western blot analysis suggested that zoledronate significantly inhibited the phosphorylation of focal adhesion kinase. Furthermore, we observed that more and more VSMCs changed from a bipolar appearance to a globular shape under inverted light microscope as zoledronate concentration increased from 0.1 to 100 microM. Images under transmission electron microscope confirmed this morphological change, and many electron density bodies were observed in zoledronate-treated VSMCs. These findings indicated that bisphosphonates' effects of suppressing atherosclerosis and neointimal hyperplasia might be due to inhibition of VSMCs, at least for zoledronate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000670     DOI: 10.1016/j.ejphar.2008.10.043

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke.

Authors:  J-H Kang; J J Keller; H-C Lin
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

2.  Re-expression of pro-fibrotic, embryonic preserved mediators in irradiated arterial vessels of the head and neck region.

Authors:  Patrick Möbius; Raimund H M Preidl; Manuel Weber; Kerstin Amann; Friedrich W Neukam; Falk Wehrhan
Journal:  Strahlenther Onkol       Date:  2017-08-15       Impact factor: 3.621

3.  Differential effect of zoledronic acid on human vascular smooth muscle cells.

Authors:  Hassan Albadawi; Mounir J Haurani; Rahmi Oklu; Jordan P Trubiano; Peter J Laub; Hyung-Jin Yoo; Michael T Watkins
Journal:  J Surg Res       Date:  2012-11-08       Impact factor: 2.192

Review 4.  Development of anticancer drugs based on the hallmarks of tumor cells.

Authors:  Natalia Bailón-Moscoso; Juan Carlos Romero-Benavides; Patricia Ostrosky-Wegman
Journal:  Tumour Biol       Date:  2014-01-29

5.  In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.

Authors:  Nadine Hagelauer; Andreas Max Pabst; Thomas Ziebart; Holger Ulbrich; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-03-26       Impact factor: 3.573

6.  Zoledronate alters natural progression of tissue-engineered vascular grafts.

Authors:  Yu-Chun Chang; Junlang Li; Gabriel Mirhaidari; Jacob Zbinden; Jenny Barker; Kevin Blum; James Reinhardt; Cameron Best; John Kelly; Toshihiro Shoji; Tai Yi; Christopher Breuer
Journal:  FASEB J       Date:  2021-10       Impact factor: 5.834

7.  Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.

Authors:  Guillaume Odri; Pui-Pui Kim; François Lamoureux; Céline Charrier; Séverine Battaglia; Jérôme Amiaud; Dominique Heymann; François Gouin; Françoise Redini
Journal:  BMC Cancer       Date:  2014-03-10       Impact factor: 4.430

8.  Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models.

Authors:  Laura J Janke; Jieun Kim; Monique A Payton; David A Jenkins; Xiangjun Cai; Emily R Finch; Yiwei Liu; Mary V Relling; Seth E Karol
Journal:  Pediatr Blood Cancer       Date:  2021-06-14       Impact factor: 3.838

9.  Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: possible role in high-glucose-induced atherogenic process.

Authors:  Guo-Ping Chen; Xiao-Qin Zhang; Tao Wu; Liang Li; Jie Han; Chang-Qing Du
Journal:  J Diabetes Res       Date:  2015-03-30       Impact factor: 4.011

10.  The Regulation of Matrix Metalloproteinase Expression and the Role of Discoidin Domain Receptor 1/2 Signalling in Zoledronate-treated PC3 Cells.

Authors:  Buket Reel; Ceren Gonen Korkmaz; Mehmet Zuhuri Arun; Gokce Yildirim; Deniz Ogut; Aysegul Kaymak; Serap Cilaker Micili; Bekir Ugur Ergur
Journal:  J Cancer       Date:  2015-08-28       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.